Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
December 30 2020 - 7:00AM
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
"Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology, today
announced that the Company will present at Biotech Showcase™
Digital 2021. The conference is taking place online between January
11-15 and will feature prerecorded sessions of company
presentations. Spiro Rombotis, President & Chief Executive
Officer, will provide an overview of the Company and progress in
key programs.
Cyclacel will host one-on-one meetings with
investors and industry stakeholders during the event. Registered
Biotech Showcase™ Digital 2021 attendees may request one-on-one
meetings with Cyclacel through the partneringONE® system.
A live webcast of the presentation will be
available through the Company's website: www.cyclacel.com. The
webcast will be archived for 90 days.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company developing innovative cancer medicines
based on cell cycle, transcriptional regulation and mitosis
biology. The transcriptional regulation program is evaluating
fadraciclib, a CDK2/9 inhibitor, in solid tumors and hematological
malignancies. The anti-mitotic program is evaluating CYC140, a PLK1
inhibitor, in advanced cancers. Cyclacel's strategy is to build a
diversified biopharmaceutical business based on a pipeline of novel
drug candidates addressing oncology and hematology indications. For
additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy,
safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding
regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual
results to differ materially include the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet
capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts |
|
|
|
Company: |
Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Russo Partners LLC, Jason Assad, (212) 845-4253,
jason.assad@russopartnersllc.com |
© Copyright 2020 Cyclacel Pharmaceuticals, Inc. All
Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Sep 2023 to Sep 2024